Drugs / GSK4427296
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04526509 | Dec 2020 → Jun 2023 | neoplasm | Adaptimmune | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK4427296 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04526509 ↗ |
| Route | Intravenous | “GSK4427296, as IV infusion” NCT04526509 ↗ |